SCHEMBL1284992

SCHEMBL1284992

Cc1cc([C@@H](C)NC(=O)c2ccc3nc(C(F)(F)F)nc(N4CCOCC4)c3c2)c(F)cc1NS(C)(=O)=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 3/20 0.41
BRAF P15056 7/20 0.38
RAF1 P04049 4/20 0.38
PIK3R1 P27986 1/20 0.38
PIK3CA P42336 1/20 0.38
MTOR P42345 1/20 0.38
LMNA P02545 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
TSHR P16473 1/20 0.37
RECQL P46063 1/20 0.37
PDE4A P27815 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37
PDE3B Q13370 1/20 0.37
PDE11A Q9HCR9 1/20 0.37
CNR1 P21554 1/20 0.36
CNR2 P34972 1/20 0.36
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1285378 0.93 TRPV1 (0.40) TRPV1
SCHEMBL1285040 0.89 TRPV1 (0.43) TRPV1TSHRKDM4E
SCHEMBL1284900 0.88 HSD17B10 (0.46) TRPV1LMNACYP1A2CYP3A4TSHR
SCHEMBL1285086 0.88 TRPV1 (0.39) TRPV1LMNA
SCHEMBL1285193 0.87 TRPV1 (0.41) TRPV1BRAFRAF1LMNACNR1
SCHEMBL1284988 0.86 LPAR2 (0.41) TRPV1LMNATSHR
SCHEMBL1284963 0.86 TRPV1 (0.50) TRPV1
SCHEMBL1644150 0.85 MAPT (0.47) BRAFLMNACYP1A2CYP3A4TSHR
SCHEMBL4556598 0.83 HSD17B10 (0.46) LMNACYP1A2CYP3A4TSHRKDM4E
SCHEMBL4556599 0.83 HSD17B10 (0.46) LMNACYP1A2CYP3A4TSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120088746-A1 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME PFIZER INC. (US) 2012-04-12 US claimed
US-20120088746-A1 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME PFIZER INC. (US) 2012-04-12 US disclosed
US-20120088746-A1 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME PFIZER INC. (US) 2012-04-12 US disclosed
US-20120088746-A1 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME PFIZER INC. (US) 2012-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088746-A1 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME TRPV1, TRPA1, TRPV2 TRPV1 1/4885BRAF 2721/4885RAF1 1192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.